Filing Flows › Trulieve Cannabis (TRLV) › Guidance & outlook
Trulieve Cannabis (TRLV) guidance and outlook
Trulieve Cannabis' 10-Q filed Nov 5, 2026 makes 11 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- We aim to be the brand of choice for medical customers in all of the markets that we serve.
- Pending regulatory approval, we plan to ramp production and retail capacity to serve all 11 regions in Texas.
- We have invested in light hydrocarbon extraction, which typically offers higher yields than other extraction methods and allows for concentrates that preserve the natural ratios of cannabinoids, terpenes, and other target compounds to better replicate the flower experience.
- By providing customers with consistent high-quality products and outstanding experiences, we aim to garner a large and loyal customer base across our distribution network.
- The Company anticipates this planned product and geographic expansion to drive immediate revenue growth in these markets.
- The Company plans to introduce Alien Labs and Connected branded products in Texas, subject to final licensure and regulatory approvals.
- If the number of consumers of medical cannabis in our markets increases, the demand for products will increase and we expect that competition will become more intense as current and future competitors offer an increasing number of diversified products and engage in price competition.
- We expect to continue to invest in several areas, including customer experience, product innovation, scaled production, marketing and branding, and distribution network expansion.
- The fair value measurement required significant management judgment related to the selection of discount rates, projected EBITDA margins and marketability discounts, all of which represent significant unobservable inputs.
- The Company has generated, and expects to continue to generate, additional cash from operations.
- The Company has applied for DEA licenses in Florida, Pennsylvania, Georgia and West Virginia, with the expected effect that the Company’s operations in those medical-only states are federally legal.
Trulieve Cannabis' latest quarter
Trulieve Cannabis, Q3 2026: revenue $230M (-20% year over year), operating margin 18.5%, net earnings $869K, operating cash flow $74.4M. The chart follows the revenue to costs, profit and cash.
Questions
What does Trulieve Cannabis expect?
We aim to be the brand of choice for medical customers in all of the markets that we serve. Pending regulatory approval, we plan to ramp production and retail capacity to serve all 11 regions in Texas. We have invested in light hydrocarbon extraction, which typically offers higher yields than other extraction methods and allows for concentrates that preserve the natural ratios of cannabinoids, terpenes, and other target compounds to better replicate the flower experience.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.